CHMP Backs Baricitinib, Lifmior for Rheumatoid Arthritis

0
234

The EMA’s CHMP recommended baricitinib for rheumatoid arthritis and Lifmior for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.
International Approvals